NCT00079131View on ClinicalTrials.gov

Oblimersen in Treating Patients With Merkel Cell Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

January 31, 2007

Conditions

Recurrent Neuroendocrine Carcinoma of the SkinStage I Neuroendocrine Carcinoma of the SkinStage II Neuroendocrine Carcinoma of the SkinStage III Neuroendocrine Carcinoma of the SkinStage IV Neuroendocrine Carcinoma of the Skin

Interventions

BIOLOGICAL

oblimersen sodium

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00079131 - Oblimersen in Treating Patients With Merkel Cell Carcinoma | Biotech Hunter | Biotech Hunter